機能性素子を用いたがん微小環境を標的とするsiRNA送達技術の開発

書誌事項

タイトル別名
  • Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device
  • Review for award 機能性素子を用いたがん微小環境を標的とするsiRNA送達技術の開発
  • Review for award キノウセイ ソシ オ モチイタ ガン ビショウ カンキョウ オ ヒョウテキ ト スル siRNA ソウタツ ギジュツ ノ カイハツ

この論文をさがす

抄録

<p>The tumor microenvironment plays a key role in cancer progression, drug resistance, metastasis, etc. To establish a new therapeutic strategy based on control of the tumor microenvironment, I have developed a lipid nanoparticle (LNP)-based in vivo small interfering RNA (siRNA) delivery system equipped with a targeting ligand. First, I established an LNP that induces membrane fusion in response to acidification after internalization by cells using the original pH-sensitive cationic lipid YSK05. A modification of polyethylene glycol to YSK05-containing LNPs allowed significant gene silencing in the human renal cell carcinoma model. Then, I attempted to establish a tumor vasculature-targeting LNP because the vasculature is responsible for the tumor microenvironment. Cyclic RGD peptide is known to be a ligand against integrin αVβ3, which is highly expressed on tumor endothelial cells (TECs). Optimized cyclic RGD peptide-modified LNP (RGD-LNP) suppressed gene expression in TECs to 50%. The inhibition of vascular endothelial cell growth factor receptor 2 (VEGFR2), which is a dominant factor in angiogenesis, by the injection of RGD-LNP significantly delayed tumor growth. Finally, I examined the effect of RGD-LNP on the tumor microenvironment. The suppression of VEGFR2 increased pericyte coverage and endothelial junctions, which indicate maturation of the vasculature. In RGD-LNP-treated mice, systemically administered nanoparticles encapsulating doxorubicin were distributed in a larger area than in untreated mice. Moreover, the therapeutic effect of doxorubicin-loaded liposomes was significantly enhanced by RGD-LNP. In conclusion, I succeeded in developing a new therapy based on regulation of the tumor microenvironment.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 139 (11), 1357-1363, 2019-11-01

    公益社団法人 日本薬学会

参考文献 (11)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ